Update on the Phase III EAGLE trial of Imfinzi
7 December 2018 07:00 GMT Update on the Phase III EAGLE trial of Imfinzi andtremelimumab in advanced head and neck cancer AstraZeneca and MedImmune, its global biologics research and development arm, today announced overall survival (OS) results for the Phase III EAGLE trial. EAGLE is a randomised, open-label, multi-centre trialevaluating Imfinzi (durvalumab) monotherapy or Imfinzi in combination with tremelimumab, an anti-CTLA4 antibody, versus standard-of-care (SoC) chemotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who experienced